• 1
    ESEMeD/MHEDEA, 2000 Investigators ESotEoMD, (ESEMeD) Project; Alonso JAM, Bernert S, Bruffaerts R, Brugha TS, Bryson H, De Girolamo GGR, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420: 2127.
  • 2
    Kessler RCDO, Frank RG, Olfson M, Pincus HA, Walters EE, Wang P, Wells KBZA. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:25152523.
  • 3
    Kessler RCDR, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999;156:19151923.
  • 4
    Lieb RBE, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;14:445452.
  • 5
    Olfson MSS, Feder A, Fuentes M, Nomura Y, Gameroff M, Weissman MM. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 2000;9:876883.
  • 6
    Maier WGM, Freyberger HJ, Linz M, Heun R, Lecrubier Y. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: A valid diagnostic entity? Acta Psychiatr Scand 2000;101:2936.
  • 7
    Wittchen HUCR, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000;15:319328.
  • 8
    Pande ACCJ, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJZD, Davidson JR, Liu-Dumaw M. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 2003;160:533540.
  • 9
    Graham SJ, Scaife JC, Langley RW, Bradshaw CM, Szabadi E, Xi L, Crumley T, Calder N, Gottesdiener K, Wagner JA. Effects of lorazepam on fear-potentiated startle responses in man. J Psychopharmacol 2005;19:249258.
  • 10
    Wolf DL, Desjardins PJ, Black PM, Francom SR, Mohanlal RW, Fleishaker JC. Anticipatory anxiety in moderately to highly-anxious oral surgery patients as a screening model for anxiolytics: Evaluation of alprazolam. J Clin Psychopharmacol 2003;23:5157.
  • 11
    Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin WA. Double-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks. Psychiatry Res 2000;94:179184.
  • 12
    Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004;161:16421649.
  • 13
    Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350357.
  • 14
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:5055.
  • 15
    Morlock RFD, Fehnel S, Williams V, Cappelleri J, Harness J, Kavoussi R, Endicott J. Development and Evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) Scale to evaluate onset of symptom relief in patients with generalized anxiety disorder. J. Psychiatric Res 2008;42:10241036.
  • 16
    Devellis R. Scale development: Theory and applications. Thousand Oaks , CA : Sage Publications, Inc., 2003.
  • 17
    Guy W. ECDEU assessment manual for psychopharmacology (US Department of Health, Education, and Welfare Publication No. 76-338). Rockville , MD : National Institute of Mental Health, 1976; pp. 218222.
  • 18
    Endicott JNJ, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993;29:321326.
  • 19
    Ware JESC Jr. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473483.
  • 20
    Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL. Generalized anxiety disorder severity scale (GADSS): A preliminary validation study. Depress Anxiety 2006;23:7782.
  • 21
    Stein DJ. Generalized anxiety disorder: Rethinking diagnosis and rating. CNS Spectr 2005;10:930934.
  • 22
    Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166:10921097.
  • 23
    Leon AC. Measuring onset of antidepressant action in clinical trials: An overview of definitions and methodology. J Clin Psychiatry 2001;62(Suppl 4):1216; discussion 37–40.
  • 24
    Montgomery SA, Bech P, Blier P, Moller HJ, Nierenberg AA, Pinder RM, Quitkin FM, Reimitz PE, Rosenbaum JF, Rush AJ, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002;63:694699.